Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma
Open Access
- 1 August 1988
- journal article
- Published by American Society of Hematology in Blood
- Vol. 72 (2) , 429-432
- https://doi.org/10.1182/blood.v72.2.429.429
Abstract
Human myeloma cells freshly isolated from 40 patients with IgG multiple myeloma (MM, 10 in stage I and 30 in stage III), were cultured for 48 hours with recombinant B cell stimulatory factor 2 (rBSF-2)/interleukin- 6 (IL-6), which is considered a major growth factor for myeloma cells. Uptake of 3H-thymidine by these purified myeloma cells was measured, and BSF-2 response was evaluated by stimulation index and delta cpm induced by rBSF-2. Myeloma cells from cases in stage I responded to rBSF-2 better than those in stage III. Moreover rBSF-2 responders also showed better response to chemotherapy. Therefore, these results suggest that in vitro response of myeloma cells to BSF-2 correlates with disease progression and clinical response in patients of MM.Keywords
This publication has 0 references indexed in Scilit: